Alpha Tau Medical Ltd DRTS 深 滬
已收盤 01-30 16:00:00 美东时间
6.94
-0.300
-4.14%
華盛通- 最 高7.30
- 今 開7.17
- 成交量 31.50万股
- 最 低 6.78
- 昨 收 7.24
- 總市值 5.90亿
- 52周最高 7.89
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 2.30
- 委 比 -12.66%
- 總股本 8504.32万
- 歷史最高 20.65
- 量 比 0.77
- 振 幅 7.18%
- 歷史最低 1.75
- 每 手 1
- 風險率 1.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
Alpha Tau Medical Ltd.在2025年取得显著进展，并计划在2026年继续推进其Alpha DaRT放射性疗法的临床试验和商业化准备。公司专注于治疗多种癌症，包括复发性皮肤鳞状细胞癌（通过ReSTART试验）、胰腺癌（IMPACT研究）、脑瘤（复发性胶质母细胞瘤的可行性研究）以及前列腺癌。Alpha Tau正在美国、欧洲、日本和以色列开展多项试验，并计划扩大产能以支持未来的商业化。此外，公司已申请其技术在日本的监管批准，并继续致力于专利保护和知识产权维护。公司现金流稳定，支持其当前的运营和未来发展。
01-29 14:00
TG Therapeutics, Clover Health Investments, Nutrien And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Nasdaq Composite falling more than 200 points ...
01-14 22:52
Alpha Tau Submits First Module Of Pre-Market Approval Application To FDA For Use Of Alpha DaRT In Treating Recurrent Cutaneous Squamous Cell Carcinoma
- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from
01-05 22:08
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
Alpha Tau Medical submitted the first module of its PMA application to the FDA for Alpha DaRT therapy targeting recurrent cutaneous squamous cell carcinoma. The FDA's modular framework allows iterative review and feedback. Concurrently, Alpha Tau is executing its ReSTART pivotal study, aiming to complete patient recruitment in Q1 2026. CEO Uzi Sofer expressed optimism about the streamlined review process, while VP Yaniv Sagie commended the team's...
01-05 14:00
Alpha Tau Expands Alpha DaRT Into Recurrent Prostate Cancer: What Investors Should Watch
Alpha Tau Medical Ltd ($DRTS) announced an update on their ongoing clinical stu...
2025-12-19 00:32
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
Alpha Tau Medical Ltd. announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, in San Francisco. The presentation will review the Company’s recent achievements and upcoming data milestones, and will be followed by institutional investor meetings. The event will also include a webcast available on the Company’s website. Alpha Tau, an Israeli onc...
2025-12-18 14:00
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
Citigroup Maintains Buy on Alpha Tau Medical, Lowers Price Target to $7
Citigroup analyst Yigal Nochomovitz maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and lowers the price target from $8 to $7.
2025-12-11 03:15
Alpha Tau Treats First U.S. Patient with Alpha DaRT for Glioblastoma
Alpha Tau Medical Ltd ( ($DRTS) ) has shared an update. On December 9, 2025, Al...
2025-12-09 22:30
Alpha Tau to Participate in December Investor Conferences
Alpha Tau Medical's CFO, Raphi Levy, will present at the 37th Annual Piper Sandler Healthcare Conference on December 3, 2025, in New York, NY, and at Sidoti's Year End Virtual Investor Conference on December 10, 2025. Both events will include investor one-on-one meetings. Alpha Tau focuses on developing alpha-radiation therapy, Alpha DaRT®, for solid tumors. Length: 122 characters.
2025-12-01 14:00
